Brief: Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura

Anthera Pharmaceuticals

10/07/2017 13:30

July 10 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O  
    * Anthera Pharmaceuticals announces result Phase 3 clinical 
study of Sollpura will be included in the cystic fibrosis 
foundation therapeutics development network 
    * Anthera Pharmaceuticals Inc - topline data are expected 
at end of 2017 or early 2018, depending on speed of patient 
enrollment. 
    * Anthera - CFF TDN approval may result in additional tdn 
investigational sites participating in study which could further 
accelerate patient recruitment in U.S. 
    * Says result Phase 3 clinical study of Sollpura approved 
by CFF TDN protocol review committee 
 
Source text for Eikon:  ID:nGNXNZZJBa  
Further company coverage:  ANTH.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))